Confounding mitigation for the exposure-response relationship of bevacizumab in colorectal cancer patients.
Fiche publication
Date publication
décembre 2023
Journal
British journal of clinical pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Pr BOUCHE Olivier
Tous les auteurs :
Lobet S, Caulet M, Paintaud G, Azzopardi N, Desvignes C, Chautard R, Borg C, Capitain O, Ferru A, Bouché O, Lecomte T, Ternant D
Lien Pubmed
Résumé
The exposure-response relationship of bevacizumab may be confounded by various factors, including baseline characteristics, time-dependent target engagement and recursive relationships between exposure and response, requiring effective mitigation. This study aimed at investigating the exposure-response relationships of bevacizumab in mCRC patients while mitigating potential biases.
Mots clés
bevacizumab, exposure-response relationship, metastatic colorectal cancer, pharmacokinetics, target-mediated drug disposition
Référence
Br J Clin Pharmacol. 2023 12 10;: